{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:46:56Z","timestamp":1791391616928,"version":"4.3.3"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:00:00Z","timestamp":1522800000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2015\/23968-6"],"award-info":[{"award-number":["2015\/23968-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.091277\/2014-00"],"award-info":[{"award-number":["88887.091277\/2014-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["425331\/2016-4"],"award-info":[{"award-number":["425331\/2016-4"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2018.00217","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T04:39:54Z","timestamp":1522816794000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":169,"title":["MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.3389","volume":"9","author":[{"given":"Giordani Rodrigues","family":"dos Passos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana Michelli","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Klein","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira Luisa","family":"Apostolos-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas Kazutoshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1590\/0004-282X20140032","article-title":"Seronegative neuromyelitis optica spectrum \u2013 the challenges on disease definition and pathogenesis","volume":"72","author":"Sato","year":"2014","journal-title":"Arq Neuropsiquiatr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1212\/NXI.0000000000000110","article-title":"Aquaporin-4 autoimmunity","volume":"2","author":"Zekeridou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1111\/ene.12679","article-title":"Neuromyelitis optica: a positive appraisal of seronegative cases","volume":"22","author":"Bernard-Valnet","year":"2015","journal-title":"Eur J Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflamm"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","article-title":"Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes","volume":"263","author":"Sep\u00falveda","year":"2016","journal-title":"J Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.4049\/jimmunol.0801888","article-title":"Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis","volume":"183","author":"McLaughlin","year":"2009","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1212\/WNL.0000000000002844","article-title":"Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD","volume":"87","author":"Wang","year":"2016","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody\u2013positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1136\/jnnp-2016-315094","article-title":"Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies","volume":"88","author":"Fujimori","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.5692\/clinicalneurol.cn-001078","article-title":"A case of anti-MOG antibody-positive multiphasic disseminated encephalomyelitis co-occurring with unilateral cerebral cortical encephalitis","volume":"57","author":"Fukushima","year":"2017","journal-title":"Rinsho Shinkeigaku"},{"key":"B21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of MOG-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J Neurochem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0161-5890(97)00005-9","article-title":"Binding of complement component Clq to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation","volume":"34","author":"Johns","year":"1997","journal-title":"Mol Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1756285611433772","article-title":"Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more","volume":"5","author":"Mayer","year":"2012","journal-title":"Ther Adv Neurol Disord"},{"key":"B25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.4049\/jimmunol.169.1.548","article-title":"High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes","volume":"169","author":"Weissert","year":"2002","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","article-title":"Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases","volume":"8","author":"Peschl","year":"2017","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/glia.1111","article-title":"T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"36","author":"Iglesias","year":"2001","journal-title":"Glia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0165-5728(95)00124-7","article-title":"The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat","volume":"63","author":"Adelmann","year":"1995","journal-title":"J Neuroimmunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1093\/brain\/awh260","article-title":"Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats","volume":"127","author":"Sakuma","year":"2004","journal-title":"Brain"},{"key":"B30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1750-3639.1998.tb00194.x","article-title":"Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology","volume":"8","author":"Storch","year":"1998","journal-title":"Brain Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1084\/jem.20021603","article-title":"Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis","volume":"197","author":"Bettelli","year":"2003","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1172\/JCI28334","article-title":"Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice","volume":"116","author":"Bettelli","year":"2006","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1172\/JCI28330","article-title":"Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell\/B cell cooperation","volume":"116","author":"Krishnamoorthy","year":"2006","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1212\/NXI.0000000000000012","article-title":"Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton","volume":"1","author":"Dale","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","article-title":"Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease","volume":"3","author":"Fujihara","year":"2012","journal-title":"Clin Exp Neuroimmunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1177\/1352458514551455","article-title":"Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody","volume":"21","author":"Ikeda","year":"2015","journal-title":"Mult Scler J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/jnnp-2015-312676","article-title":"Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies","volume":"87","author":"Kaneko","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: a clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1212\/NXI.0000000000000335","article-title":"ADEM-like presentation, anti-MOG antibodies, and MS pathology: two case reports","volume":"4","author":"K\u00f6rtv\u00e9lyessy","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u201cpattern II multiple sclerosis\u201d and brain biopsy findings in a MOG-IgG-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult Scler J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1212\/NXI.0000000000000175","article-title":"Fulminant demyelinating encephalomyelitis","volume":"2","author":"Di Pauli","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0165-5728(99)00010-7","article-title":"Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG)","volume":"97","author":"Brehm","year":"1999","journal-title":"J Neuroimmunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/eji.200425050","article-title":"Frontline: epitope recognition on the myelin\/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination","volume":"34","author":"von B\u00fcdingen","year":"2004","journal-title":"Eur J Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/7651_2015_223","article-title":"Detection of autoantibodies against myelin oligodendrocyte glycoprotein in multiple sclerosis and related diseases","volume":"1304","author":"Spadaro","year":"2015","journal-title":"Methods Mol Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2014","journal-title":"Mult Scler"},{"key":"B51","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands","volume":"23","author":"van Pelt","year":"2015","journal-title":"Eur J Neurol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1001\/archneurol.2011.2956","article-title":"Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis","volume":"69","author":"Rostasy","year":"2012","journal-title":"Arch Neurol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1177\/1352458512470310","article-title":"Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica","volume":"19","author":"Rost\u00e1sy","year":"2013","journal-title":"Mult Scler"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B56","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/1352458515591071","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications","volume":"22","author":"Cobo-Calvo","year":"2015","journal-title":"Mult Scler"},{"key":"B57","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/1352458514551454","article-title":"Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis","volume":"21","author":"Hyun","year":"2015","journal-title":"Mult Scler"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","journal-title":"J Neuroinflamm"},{"key":"B60","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/1352458515614093","article-title":"The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients","volume":"22","author":"Siritho","year":"2015","journal-title":"Mult Scler J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s11427-015-4997-y","article-title":"Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD","volume":"59","author":"Yan","year":"2016","journal-title":"Sci China Life Sci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jns.2013.08.034","article-title":"Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica","volume":"335","author":"Woodhall","year":"2013","journal-title":"J Neurol Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B64","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement \u2013 frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1212\/NXI.0000000000000257","article-title":"Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis","volume":"3","author":"Spadaro","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B67","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12883-014-0224-x","article-title":"Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report","volume":"14","author":"Amano","year":"2014","journal-title":"BMC Neurol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12883-017-0858-6","article-title":"Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report","volume":"17","author":"Nakamura","year":"2017","journal-title":"BMC Neurol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B70","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Pr\u00f6bstel","year":"2011","journal-title":"Neurology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2015","journal-title":"Mult Scler"},{"key":"B72","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B73","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e0170847","DOI":"10.1371\/journal.pone.0170847","article-title":"Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study","volume":"12","author":"Stiebel-Kalish","year":"2017","journal-title":"PLoS One"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders. Comparison according to the phenotype and serostatus","volume":"3","author":"Sep\u00falveda","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1177\/1352458516631038","article-title":"Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases","volume":"22","author":"Baumann","year":"2016","journal-title":"Mult Scler"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1212\/NXI.0000000000000081","article-title":"Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children","volume":"2","author":"Hacohen","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"4","author":"Ketelslegers","year":"2015","journal-title":"Mult Scler J"},{"key":"B79","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2015","journal-title":"Mult Scler J"},{"key":"B80","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","article-title":"Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases","volume":"191","author":"Mayer","year":"2013","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.11251\/ojjscn.48.199","article-title":"[Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis]","volume":"48","author":"Oshiro","year":"2016","journal-title":"No To Hattatsu"},{"key":"B83","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e007766","DOI":"10.1136\/bmjopen-2015-007766","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis","volume":"5","author":"Nakajima","year":"2015","journal-title":"BMJ Open"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/787630","article-title":"Plasma exchange in severe attacks of neuromyelitis optica","volume":"2012","author":"Bonnan","year":"2012","journal-title":"Mult Scler Int"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1136\/jnnp.2005.086306","article-title":"Fulminant Devic disease successfully treated by lymphocytapheresis","volume":"77","author":"Nozaki","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"B89","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","journal-title":"Mult Scler"},{"key":"B90","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jns.2014.01.035","article-title":"Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab","volume":"339","author":"Kitley","year":"2014","journal-title":"J Neurol Sci"},{"key":"B91","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"B92","doi-asserted-by":"publisher","first-page":"513","DOI":"10.5692\/clinicalneurol.53.513","article-title":"[A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment]","volume":"53","author":"Izaki","year":"2013","journal-title":"Clin Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2018.00217\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T22:40:43Z","timestamp":1522968043000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fneur.2018.00217\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,4]]},"references-count":92,"alternative-id":["10.3389\/fneur.2018.00217"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2018.00217","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,4]]},"article-number":"217"}}